Galectin Therapeutics (NASDAQ:GALT) had its price target raised by stock analysts at Roth Capital from $3.00 to $8.00 in a research report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Roth Capital’s price target indicates a potential upside of 82.65% from the company’s current price.

Several other brokerages have also weighed in on GALT. ValuEngine lowered Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. HC Wainwright increased their target price on Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Seaport Global Securities reaffirmed a “buy” rating and issued a $5.00 target price on shares of Galectin Therapeutics in a research report on Friday, October 6th. Finally, Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. Galectin Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $5.55.

Galectin Therapeutics (GALT) opened at $4.38 on Thursday. The firm has a market capitalization of $137.57, a price-to-earnings ratio of -7.96 and a beta of 2.54. Galectin Therapeutics has a 52-week low of $0.94 and a 52-week high of $4.80.

Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. analysts predict that Galectin Therapeutics will post -0.52 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in GALT. Vanguard Group Inc. increased its holdings in Galectin Therapeutics by 18.2% in the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after purchasing an additional 134,165 shares in the last quarter. Advisor Group Inc. increased its holdings in Galectin Therapeutics by 10.4% in the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock valued at $1,191,000 after purchasing an additional 45,700 shares in the last quarter. Virtu KCG Holdings LLC increased its holdings in Galectin Therapeutics by 24.4% in the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after purchasing an additional 21,008 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Galectin Therapeutics by 4.4% in the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares in the last quarter. Hedge funds and other institutional investors own 10.77% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Galectin Therapeutics (GALT) Price Target Increased to $8.00 by Analysts at Roth Capital” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/04/galectin-therapeutics-galt-price-target-increased-to-8-00-by-analysts-at-roth-capital.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.